Declared competing interests of authors: JEE has received consultancy fees from GlaxoSmithKline and performed paid work for the Department of Health, England. KGN has received H5 avian influenza vaccines from Novartis and H1N1 pandemic influenza vaccines from GlaxoSmithKline and Baxter to facilitate MRC-and NIHR-funded trials. In addition, he has received consultancy fees from Novartis and GlaxoSmithKline and lecture fees from Baxter. A colleague of KGN at the University Hospitals of Leicester NHS Trust was principal investigator and recipient of research funding from Roche on antiviral resistance, and from Novartis on pandemic H1N1 vaccines. JSNVT has received funding to attend influenza-related meetings, lecture and consultancy fees and research funding from several influenza antiviral drug and vaccine manufacturers, including GlaxoSmithKline